Podcast Episodes

Episode 168: Mechanisms of response to PD1 therapy in renal cancer

Season 1 Episode 168

David Braun gives an overview.

4 years, 6 months ago

View Episode

Episode 167: Highlights from EIKCS oral session

Season 1 Episode 167

Michael Staehler gives an overview of the session. 

4 years, 6 months ago

View Episode

Episode 166: Prostate cancer debate: doublet vs triplet first line therapy

Season 1 Episode 166

Rana McKay and Kim Chi discuss this topic, with unexpected conclusions....

4 years, 6 months ago

View Episode

Episode 165: Paper of the Month - ENZAMET quality of life data

Season 1 Episode 165

Martin Stockler describes this paper, which shows mixed effects of enza on QOL in prostate cancer.

4 years, 6 months ago

View Episode

Episode 164: Paper of the Month - what can we learn from R3 ipilimumab/nivolumab in gastric cancer

Yelena Janjigian describes ipi/nivo vs nivo chemo vs chemo in Gastric cancer - published in Nature

4 years, 7 months ago

View Episode

Episode 163: The Uromigos Debate - Treatment of favorable risk renal cancer

Season 1 Episode 163

David McDermott attempts to get his point across...again. 

4 years, 7 months ago

View Episode

Episode 162: Debate - Adjuvant nivolumab for bladder cancer

Season 1 Episode 162

Matt Galski and Tom Powles take the FDA and EMA approach respectively.

4 years, 7 months ago

View Episode

Episode 161: Platinum eligibility in urothelial cancer

Season 1 Episode 161

Shilpa Gupta describes cisplatin and platinum eligibility. 

4 years, 7 months ago

View Episode

Episode 160: APCCC - PMSA PET as a diagnostic

Season 1 Episode 160

Stefano Fanti describes this topic. 

4 years, 8 months ago

View Episode

Episode 159: ASCO GU 2022 Adjuvant and neoadjuvant therapy in renal cancer

Season 1 Episode 161

Axel Bex discusses these topics.

4 years, 8 months ago

View Episode